Navigation Links
Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
Date:5/11/2009

HILLSBOROUGH, Calif., May 11 /PRNewswire-FirstCall/ -- Apex Bioventures Acquisition Corporation (NYSE Amex: PEX) (the "Company") announced today that it has received notice from NYSE Amex LLC (the "Exchange") that the plan of compliance submitted by the Company has been accepted by the Exchange and the Company has been granted an extension until August 11, 2009 to regain compliance with the continued listing standards of the Exchange.

As reported in a press release dated February 13, 2009, the Company received notice from the Exchange on February 10, 2009 indicating that the Company is not in compliance with one of the requirements for continued listing on the Exchange due to the Company's failure to hold an annual meeting during calendar year 2008. The Company was afforded the opportunity to submit to the Exchange a plan of compliance and on March 6, 2009, submitted its plan to the Exchange.

The Company will be subject to periodic review by Exchange staff during the extension period. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the extension period could result in the Company being delisted from the Exchange.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements are based on current expectations and are subject to numerous risks, assumptions and uncertainties, many of which change over time and are beyond the Company's control. Actual results may differ materially from those anticipated in any forward-looking statement and you should not place any undue reliance on such forward-looking statements. More detailed information about the Company and risk factors that may affect the realization of forward-looking statements, including forward-looking statements in this press release, is set forth in the Company's filings with the Securities and Exchange Commission. The Company urges investors and security holders to read those documents free of charge at the Commission's web site at http://www.sec.gov. Interested parties may also obtain these documents free of charge from the Company. Forward-looking statements speak only as to the date they are made, and except for any obligation under the U.S. federal securities laws, the Company undertakes no obligation to publicly update any forward-looking statement as a result of new information, future events or otherwise.


'/>"/>
SOURCE Apex Bioventures Acquisition Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Newbridge Securities Corporation Forms BioVentures Division
2. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
3. CRO Acquisition Seen Boosting Activity, Positioning ASG, Inc., for New Growth in Q2
4. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
5. Gen-Probe Completes Acquisition of Tepnel Life Sciences
6. China Biologic Products Completes Acquisition of 35% Interest in Xian Huitian Blood Products Co., Ltd.
7. RoundTable Healthcare Partners Facilitates Product Acquisition for CorePharma
8. JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media
9. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
10. BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009
11. Morningstar Healthcare Analysts to Discuss Top 15 Biotech Acquisition Targets on Wednesday, March 4 at 11 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
Breaking Biology News(10 mins):